Evidence map›Paper›PMID 41114085›Full record

ArticleJournal of diabetes and metabolic disorders2025

A dual

Amine Hssaine, Fatima Ez-Zahra Ousaid, Imane Nait Irahal, Fatima Zahra Khaddach, Miloud El Karbane, Mohamed Azougagh, Noureddine Bourhim, Brahim Benaji

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amine HssaineGroup Research of Biomedical Engineering and Pharmaceuticals Sciences - Department of Health Technologies Engineering - Graduate School of Arts and Crafts (ENSAM), Mohammed V University, Rabat, Morocco.
Fatima Ez-Zahra OusaidHealth and Environment Laboratory - Biochemistry, Biotechnology and Immuno physiopathology Team - Faculty of Sciences Ain Chock, University Hassan II of Casablanca, Casablanca, Morocco.
Imane Nait IrahalHealth and Environment Laboratory - Biochemistry, Biotechnology and Immuno physiopathology Team - Faculty of Sciences Ain Chock, University Hassan II of Casablanca, Casablanca, Morocco.
Fatima Zahra KhaddachGroup Research of Biomedical Engineering and Pharmaceuticals Sciences - Department of Health Technologies Engineering - Graduate School of Arts and Crafts (ENSAM), Mohammed V University, Rabat, Morocco.
Miloud El KarbaneAnalytical Chemistry and Bromatology Laboratory - Research Center of Drugs Sciences -Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
Mohamed AzougaghGroup Research of Biomedical Engineering and Pharmaceuticals Sciences - Department of Health Technologies Engineering - Graduate School of Arts and Crafts (ENSAM), Mohammed V University, Rabat, Morocco.
Noureddine BourhimHealth and Environment Laboratory - Biochemistry, Biotechnology and Immuno physiopathology Team - Faculty of Sciences Ain Chock, University Hassan II of Casablanca, Casablanca, Morocco.
Brahim BenajiGroup Research of Biomedical Engineering and Pharmaceuticals Sciences - Department of Health Technologies Engineering - Graduate School of Arts and Crafts (ENSAM), Mohammed V University, Rabat, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired glucose metabolism. Glimepiride, a sulfonylurea drug, is commonly used to manage blood glucose levels in T2DM patients. However, the efficacy of various active pharmaceutical ingredients (APIs) of Glimepiride has not been thoroughly compared. Here, we systematically evaluate nine Glimepiride APIs for their modulation of oxidative stress pathways Graphical Abstract:

Indexed as

Aldose reductaseGlimepirideMolecular dockingOxidative stressType 2 diabetes mellitus

Identifiers

PMID41114085
PMCPMC12528524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.